Pyroglutamate-modified amyloid-β (pE3-Aβ) is a highly pathogenic Aβ species that accumulates within amyloid plaques and contributes to aggregation, neuroinflammation and neuronal dysfunction in Alzheimer’s disease (AD). Researchers from Sound Biologics (Qilu Puget Sound Biotherapeutic Corp.) described the preclinical profile of PSB-229, a novel brain-shuttled anti-pE3-Aβ antibody in models of AD.
Fosun Pharma subsidiary Fosun Pharmaceutical Industrial Development (Shenzhen) Co. Ltd. has received approval from China’s National Medical Products Administration (NMPA) to commence clinical trials for FXR-0906 for the treatment of hypertriglyceridemia.
Tempest Therapeutics Inc. has announced details of its pipeline of in vivo CAR T product candidates differentiated by a CD7-targeted mRNA/LNP delivery approach, with application in the fields of oncology and immunology. Tempest’s in vivo CAR T platform, CD7-targeted mRNA lipid nanoparticle (CD7-tLNP), offers broader T-cell reach, enhanced delivery efficiency and scalable in vivo CAR T.
Ascletis Pharma Inc. has selected a fixed-dose combination of ASC-48, an oral small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) agonist, and ASC-30, an oral small-molecule glucagon-like peptide 1 receptor (GLP-1R) agonist, for clinical development for obesity.
Excessive fibrinolysis is a major driver of bleeding across multiple clinical settings, including heavy menstrual bleeding and other hemorrhagic disorders. Researchers from Hemab ApS presented preclinical data on HMB-003, a long-acting plasmin inhibitor that directly targets the enzyme’s active site to achieve sustained antifibrinolytic activity.
Nuoshen Pharmaceutical (Shanghai) Co. Ltd. has disclosed new NLRP3 inflammasome inhibitors potentially useful for the treatment of neuroinflammation, multiple sclerosis, amyotrophic lateral sclerosis, Alzheimer’s, Parkinson’s and Huntington’s disease.
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. has prepared and tested new bispecific antibody-drug conjugates (ADCs) consisting of a bispecific antibody or antigen-binding fragments targeting B7 homolog 3 (B7-H3; CD276) and delta-like protein 3 (DLL3) linked to cytotoxic drug; they are described as potentially useful for the treatment of cancer.
Alphina Therapeutics Inc. has identified new nicotinamide phosphoribosyltransferase (NAmPRTase; Nampt) inhibitors potentially useful for the treatment of autoimmune and metabolic diseases, inflammatory disorders and cancer.
Neolaia Inc. has discovered new 6,5-bicyclic compounds acting as ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 (CD38) inhibitors potentially useful for the treatment of cancer, neurodegeneration, fibrosis, renal, inflammatory, autoimmune, metabolic and cardiovascular disease, among others.
RSS
